Relapsed/refractory multiple myeloma–related outcome based on cardiotoxicity
| . | No cardiac events (N = 67) . | Cardiac events (N = 11) . | P . |
|---|---|---|---|
| Day 30 response | .175 | ||
| sCR | 13 (19.4%) | 5 (50.0%) | |
| CR | 4 (6.0%) | 0 (0.0%) | |
| VGPR | 9 (13.4%) | 2 (20.0%) | |
| PR | 19 (28.4%) | 1 (10.0%) | |
| SD | 13 (19.4%) | 0 (0.0%) | |
| PD | 9 (13.4%) | 2 (20.0%) | |
| Day 90 response | .362 | ||
| sCR | 10 (18.5%) | 4 (50.0%) | |
| CR | 7 (13.0%) | 1 (12.5%) | |
| VGPR | 3 (5.6%) | 1 (12.5%) | |
| PR | 21 (38.9%) | 1 (12.5%) | |
| SD | 2 (3.7%) | 0 (0.0%) | |
| PD | 11 (20.4%) | 1 (12.5%) | |
| Overall response rate at day 30 | 45 (67.2%) | 8 (80.0%) | .652 |
| Overall response rate at day 90 | 41 (75.9%) | 7 (87.5%) | .781 |
| No progression of disease at end of follow-up | 46 (68.7%) | 6 (54.5%) | .565 |
| Alive at end of follow-up | 58 (86.6%) | 7 (63.6%) | .146 |
| . | No cardiac events (N = 67) . | Cardiac events (N = 11) . | P . |
|---|---|---|---|
| Day 30 response | .175 | ||
| sCR | 13 (19.4%) | 5 (50.0%) | |
| CR | 4 (6.0%) | 0 (0.0%) | |
| VGPR | 9 (13.4%) | 2 (20.0%) | |
| PR | 19 (28.4%) | 1 (10.0%) | |
| SD | 13 (19.4%) | 0 (0.0%) | |
| PD | 9 (13.4%) | 2 (20.0%) | |
| Day 90 response | .362 | ||
| sCR | 10 (18.5%) | 4 (50.0%) | |
| CR | 7 (13.0%) | 1 (12.5%) | |
| VGPR | 3 (5.6%) | 1 (12.5%) | |
| PR | 21 (38.9%) | 1 (12.5%) | |
| SD | 2 (3.7%) | 0 (0.0%) | |
| PD | 11 (20.4%) | 1 (12.5%) | |
| Overall response rate at day 30 | 45 (67.2%) | 8 (80.0%) | .652 |
| Overall response rate at day 90 | 41 (75.9%) | 7 (87.5%) | .781 |
| No progression of disease at end of follow-up | 46 (68.7%) | 6 (54.5%) | .565 |
| Alive at end of follow-up | 58 (86.6%) | 7 (63.6%) | .146 |
Overall response rate was designated when there was partial response or better (sCR, CR, VGPR, or PR).
PFS rate was designated when there was no progression of disease (sCR, CR, VGPR, PR, or SD).
OS was calculated as the time between the date of infusion and date of death from any cause or last contact, and PFS was calculated as the time between the date of infusion and date of progression, death, or last contact.
CR, complete response; PD, progression of disease; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.